NAV

IL15-NK Cell

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
IL15-NK Cell
DrugBank Accession Number
DB15725
Background

Natural killer (NK) cells can be incubated with ‘feeder cells’ expressing certain cytokines prior to maturation to enhance their activity. In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
  • IL15-Natural Killer Cell
External IDs
  • IL15-NK cells
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

IL-15 is a key cytokine in NK cell development and function; the IL-15 receptor (IL-15R) is constitutively expressed in both the CD56bright and CD56dim matured NK cells. Activation of the IL-15R involves 3 downstream pathways: JAK1/3/STAT3/5, P13K/Akt/mTOR, and Ras/Raf/MEK/ERK. It was shown that ‘priming’ NK-cells with IL-15 markedly enhanced anti-tumor responses which included cytotoxicity, degranulation, and cytokine production.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Robinson TO, Schluns KS: The potential and promise of IL-15 in immuno-oncogenic therapies. Immunol Lett. 2017 Oct;190:159-168. doi: 10.1016/j.imlet.2017.08.010. Epub 2017 Aug 16. [Article]
  2. Rezvani K, Rouce R, Liu E, Shpall E: Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther. 2017 Aug 2;25(8):1769-1781. doi: 10.1016/j.ymthe.2017.06.012. Epub 2017 Jun 28. [Article]
  3. Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, Sullivan RP, Jewell BA, Becker-Hapak M, Schappe T, Abdel-Latif S, Ireland AR, Jaishankar D, King JA, Vij R, Clement D, Goodridge J, Malmberg KJ, Wong HC, Fehniger TA: CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. J Clin Invest. 2017 Nov 1;127(11):4042-4058. doi: 10.1172/JCI90387. Epub 2017 Oct 3. [Article]
  4. Tornroos H, Hagerstrand H, Lindqvist C: Culturing the Human Natural Killer Cell Line NK-92 in Interleukin-2 and Interleukin-15 - Implications for Clinical Trials. Anticancer Res. 2019 Jan;39(1):107-112. doi: 10.21873/anticanres.13085. [Article]
  5. Choi SS, Chhabra VS, Nguyen QH, Ank BJ, Stiehm ER, Roberts RL: Interleukin-15 enhances cytotoxicity, receptor expression, and expansion of neonatal natural killer cells in long-term culture. Clin Diagn Lab Immunol. 2004 Sep;11(5):879-88. doi: 10.1128/CDLI.11.5.879-888.2004. [Article]
  6. TheScientist: Natural Killer Cell Therapies Catch Up to CAR T [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2Unknown StatusTreatmentCoronavirus Disease 2019 (COVID‑19)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at August 11, 2020 18:36 / Updated at October 07, 2021 12:09